Our Alzheimer's Program is on the way to proving a novel concept that underpins a new disease definition and treatments for Alzheimer's

​

We aim to influence world efforts by proving how Alzheimer's dementia arises. This is because, in science, concepts drive therapeutic efforts. We are focused on developing a new theory of Alzheimer's and in turn, aim to underpin a new therapeutic approach.

​

 

We made discoveries in our Parkinson's Program that are significant for disease management and for patients

​

For many years we provided evidence and argued that inflammation in the brain is crucial to the dysfunction that leads to Parkinson's. In 2021-2, we made a new discovery, using the latest sophisticated technologies. Specifically, we identified a new mechanism that propels the inflammation that drives Parkinson's 

​

In 2021-2, we discovered a molecule that controls the activation of microglia cells. We also discovered that when this molecule is blocked, inflammation is reduced. Additionally, we discovered that neurodegeneration, and therefore the Parkinson's disease, is reduced when this molecule is blocked. Equally exciting, we found that this molecule is also involved in the development of l-dopa induced dyskinesias, which are a debilitating side effect that occurs following long-term Parkinson's treatment. 

​

​